A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT ID: NCT07116031
Last Updated: 2026-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
37 participants
INTERVENTIONAL
2025-12-02
2031-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of Phase 1 is to determine the PK profiles and to establish the Recommended Pediatric Equivalent Dose (RPED) of belumosudil in participants aged 1 to \<12 years with active moderate to severe cGVHD. Upon completion and evaluation of Phase 1, Phase 2 will commence with the purpose of determining safety and efficacy (ORR by 24 weeks) of belumosudil in participants aged 1 to \<18 years.
Study details include:
The end of study is defined as 3 years after the last participant is recruited or all participants have discontinued treatment, or have died, whichever comes first.
Minimum of 6 participants ages 1 to 6 years will be enrolled for each phase of study
Individual participant duration on study will consist of:
Up to 4 weeks for screening. Treatment until clinically significant progression of cGVHD, relapse/recurrence of the underlying disease, start of a new systemic treatment for cGVHD, experience of an unacceptable adverse event, request from participant or Investigator, or until the end of the study is reached, whichever comes first.
4 weeks of post treatment safety follow-up. Long-term follow-up until death or end of study, whichever occurs first.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
NCT03640481
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
NCT07135973
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
NCT05567406
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
NCT05996627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
belumosudil
Participant will take IMP with a meal approximately the same time each morning. IMP dose will be according to weight and will be increased to daily dose of twice a day (BID) in participants who concomitantly receive proton pump inhibitors (PPIs) or strong CYP3A4 inducers. No concomitant PPIs are allowed during Phase 1 up to and including Cycle 1 Day 15. From Day 16 onwards, PPIs will be permitted, resulting in an increased dose of Belumosudil to BID. No concomitant strong CYP3A4 inducers are allowed during Phase 1.
Belumosudil
Pharmaceutical form:Oral suspension -Route of administration:Oral or nasogastric tube
Belumosudil
Pharmaceutical form:Tablet formulation-Route of administration:Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belumosudil
Pharmaceutical form:Oral suspension -Route of administration:Oral or nasogastric tube
Belumosudil
Pharmaceutical form:Tablet formulation-Route of administration:Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has undergone an allogeneic HCT
* Has active moderate to severe cGVHD, defined using the NIH Consensus diagnosis and staging criteria for which systemic therapy is required
* cGVHD is refractory to or has recurred after at least 2 prior lines of systemic treatment
* Has received at least two lines of prior systemic therapy for cGVHD, but no more than 5 lines.
* If participant receives corticosteroid therapy for cGVHD, the dose must be stable for at least 2 weeks prior to the first dose of the IMP
* Has a Lansky-Play (if aged ≤16) or Karnofsky (if aged \>16) performance scale of ≥60
* Body weight of 8 kg and above
* Contraceptive use by sexually active male and female should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* Life expectancy of \>6 months
* Participants can take the IMP orally or via a nasogastric tube
Exclusion Criteria
* Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years prior to the first dose of the IMP
* History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study (such as malabsorption syndromes, active, uncontrolled infections, or poorly controlled psychiatric disease)
* Has a forced expiratory volume (in the first second; FEV1) ≤39% or has lung score of 3
* Female participants who are pregnant or breastfeeding
* Current treatment with systemic agents for cGVHD (apart from corticosteroids and calcineurin inhibitors), such as ibrutinib, ruxolitinib, sirolimus, mycophenolate (MMF), methotrexate, rituximab, imatinib, extracorporeal photopheresis (ECP) and any investigational cGVHD treatment. Prior treatment with these agents and/or therapy is allowed with a washout of at least 28 days or 5 half-lives, whichever is shorter, prior to the first dose of the IMP
* The use of herbal and recreational drugs within 7 days before the start of study intervention
* Participant has had previous exposure to belumosudil
* Administration of live or live-attenuated vaccines is prohibited within 28 days or 5 elimination half-lives of the respective vaccine, whichever is longer, prior to IMP administration and until study intervention discontinuation
* Treatment with any non-GVHD investigational agent, or any investigational device or procedure, within 28 days (or 5 half-lives, whichever is longer) of enrollment, prior to the first dose of the IMP
* For Phase 1 only: Administration with strong CYP3A4 inducers is not allowed within 14 days or 5 half-lives (whichever is longer) of the first dose of IMP until the study intervention discontinuation.
* For Phase 1 only: PPIs are not allowed within 1 day or 5 half-lives (whichever is longer) of the first dose of IMP and Day 15 of Cycle 1. They can be restarted on Cycle 1 Day 16.
* Absolute neutrophil count \<1.0 × 109/L. The use of granulocyte-colony stimulating factor (G-CSF) is not allowed to reach this level during screening
* Platelet count \<25 × 109/L. Platelet transfusions are not allowed within 72 hours before hematology screening test. Participants with platelet transfusion refractoriness will be excluded. (Participants who have suboptimal responses to at least 2 transfusions will be considered as platelet transfusion refractory)
* Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>3× upper limit of normal (ULN) (\> 5x ULN if abnormalities are due to cGVHD)
* Total bilirubin \>1.5 × ULN (\>3 x ULN if Gilbert's syndrome)
* Glomerular filtration rate (GFR) \<30 mL/min/1.73 m2 using the revised Bedside Schwartz calculator
* Participants with an active viral disease including hepatitis B virus (HBV) and hepatitis C virus (HCV)
* Active uncontrolled Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection
* Known history of human immunodeficiency virus (HIV)
* Not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meiji Seika Pharma Co., Ltd.
INDUSTRY
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center- Site Number : 8400001
New York, New York, United States
Texas Children's Hospital - Baylor - PIN- Site Number : 8400008
Houston, Texas, United States
Investigational Site Number : 0560003
Ghent, , Belgium
Investigational Site Number : 0560001
Leuven, , Belgium
Investigational Site Number : 1560001
Shanghai, , China
Investigational Site Number : 1560004
Shenzhen, , China
Investigational Site Number : 1560002
Suzhou, , China
Investigational Site Number : 2500002
Marseille, , France
Investigational Site Number : 2500001
Paris, , France
Investigational Site Number : 2760001
Berlin, , Germany
Investigational Site Number : 3760005
Haifa, , Israel
Investigational Site Number : 3760002
Jerusalem, , Israel
Investigational Site Number : 3760001
Tel Aviv, , Israel
Investigational Site Number : 3760003
Tel Litwinsky, , Israel
Investigational Site Number : 3800001
Roma, , Italy
Investigational Site Number : 5280001
Utrecht, , Netherlands
Investigational Site Number : 7240003
Esplugues de Llobregat, Catalunya [Cataluña], Spain
Investigational Site Number : 7240002
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240001
Barcelona, , Spain
Investigational Site Number : 8260002
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial Transparency email recommended (Toll free for US & Canada)
Role: CONTACT
Related Links
Access external resources that provide additional context or updates about the study.
DFI17893 Plain Language Results Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1281-0103
Identifier Type: REGISTRY
Identifier Source: secondary_id
2024-511508-18
Identifier Type: REGISTRY
Identifier Source: secondary_id
DFI17893
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.